At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 859 enrolled
Drug / intervention
Gatifloxacin 0.5% eye drops +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis
In Brief
A Phase 3 clinical trial evaluating Gatifloxacin 0.5% eye drops and placebo eye drops for Bacterial Conjunctivitis. Completed, enrolled 859 participants across 2 sites in 2 countries.
Detailed Summary
The study will determine the safety and efficacy of gatifloxacin eye drops in patients with bacterial conjunctivitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Conjunctivitis
CountriesIndia, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2007
Enrollment StartFeb 2008
Primary CompletionJan 2009
TodayJul 2026
First PostedAug 20, 2007
Enrollment StartFeb 1, 2008
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 18.9 years ago
Interventions
Gatifloxacin 0.5% eye dropsdrug
Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
placebo eye dropsdrug
Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily